Loading clinical trials...
Loading clinical trials...
Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study
There are still uncertainties about the existence of protective immunity and the duration of protective antibodies in patients infected with SARS-CoV-2. Serological testing is an appropriate tool for epidemiological investigations to assess the persistence of antibodies over time. The nature of the immune response induced by this virus is also poorly understood. This ancillary study aims at assessing the immunological characteristics of patients that participated in the NOSO-COR study at Hospices Civils de Lyon six and twelve months after the initial infectious episode. Two visits will be scheduled at 6 and 12 months (± 1 month) after the initial SARS-CoV-2 infectious episode, Blood, saliva and nasopharyngeal samples will be collected for seroprevalence and immunological investigation.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Service épidémiologie, Hopital édouard Herriot
Lyon, Rhone, France
hopital Edouard Herriot
Lyon, France
Start Date
November 23, 2020
Primary Completion Date
May 12, 2021
Completion Date
May 12, 2021
Last Updated
September 5, 2025
189
ACTUAL participants
Collection of blood, salivary and nasopharyngeal samples.
OTHER
Lead Sponsor
Hospices Civils de Lyon
NCT04290780
NCT06379061
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04332016